This content is machine translated Non-small cell lung cancer (NSCLC) Treatment strategies in metastatic ALK-positive and ROS1-positive NSCLC. The therapy of ALK-positive or ROS1-positive NSCLC has evolved greatly in recent years with the availability of various ALK or ROS1 inhibitors. This CME will summarize and discuss the current…
